

DAC
Box - 508

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/831,621	
	Filing Date	May 10, 2001 JAN 24 2006	
	First Named Inventor	BAUM et al.	
	Art Unit	To be determined OFFICE OF PETITIONS	
	Examiner Name	To be determined	
Total Number of Pages in This Submission	36	Attorney Docket Number	NEU-00119.P.1

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input checked="" type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Copy of Acceptance of Power of Attorney 2. Response to Notification of Missing Req. 3. Declaration 4. Sequence Listing (paper and diskette)
<div>Remarks</div> <div>Also enclosed, 5. Statement under 37 CFR 1.821 6. Postcard</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	David R. Preston & Associates, APC		
Signature			
Printed name	David R. Preston		
Date	1/17/06	Reg. No.	38,710

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Reza Savari	Date	1-17-06

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT
ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number (Optional)

NEU-00119.P.1

First named inventor: BAUM et al.

Application No.: 09/831,621

Art Unit: To be determined

Filed: May 10, 2001

Examiner: To be determined

Title: NOVEL DNAs AND POLYPEPTIDES

#10

Attention: Office of Petitions

Mail Stop Petition

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

FAX (571) 273-8300

RECEIVED

22 FEB 2006

Legal Staff
International Division

RECEIVED

JAN 24 2006

OFFICE OF PETITIONS

NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (571) 272-3282.

The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained.

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee;
- (2) Reply and/or issue fee;
- (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

☒ Small entity-fee \$ 750.00 (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27.

☐ Other than small entity - fee \$ _____ (37 CFR 1.17(m))

2. Reply and/or fee

A. The reply and/or fee to the above-noted Office action in the form of Declaration and Sequence Listing (paper copy and diskette) (identify type of reply):

- ☐ has been filed previously on _____.
- ☒ is enclosed herewith.

B. The issue fee and publication fee (if applicable) of \$ _____.

- ☐ has been paid previously on _____.
- ☐ is enclosed herewith.

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

- ☒ Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.
- ☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. STATEMENT: The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional. [NOTE: The United States Patent and Trademark Office may require additional information if there is a question as to whether either the abandonment or the delay in filing a petition under 37 CFR 1.137(b) was unintentional (MPEP 711.03(c), subsections (III)(C) and (D)).]

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

<p><u></u> Signature</p> <p>_____ Dr. Warren Young Typed or printed name</p> <p>_____ Neurome, Incorporated Address</p> <p>_____ 11149 North Torrey Pines Rd. Suite 100, San Diego, CA 92037-1031 Address</p>	<p><u>1-11-06</u> Date</p> <p>_____ Registration Number, if applicable</p> <p><u>858-677-0466</u> Telephone Number</p>
---	---


- Enclosures: ☒ Fee Payment
- ☒ Reply
- ☐ Terminal Disclaimer Form
- ☐ Additional sheets containing statements establishing unintentional delay
- ☒ Other: Declaration, Sequence Listing (paper copy and diskette), and Postcard

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.
- ☐ Transmitted by facsimile on the date shown below to the United States Patent and Trademark Office as (571) 273-8300.

1-17-06
Date


Signature

Reza Savari
Typed or printed name of person signing certificate

O I P E I A P S S

JAN 20 2006

PTO/SB/17 (12-04v2)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.
Pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).**FEE TRANSMITTAL**
For FY 2005☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 750.00

Complete if Known

Application Number	09/831,621
Filing Date	May 10, 2001
First Named Inventor	BAUM et al.
Examiner Name	To be determined
Art Unit	To be determined
Attorney Docket No.	NEU-00119.P.1

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☐ Deposit Account Deposit Account Number: 501321 Deposit Account Name: David R. Preston & Assoc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity Fee (\$)
50	25

Each independent claim over 3 (including Reissues)

200	100
-----	-----

Multiple dependent claims

360	180
-----	-----

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims

Fee (\$)	Fee Paid (\$)
----------	---------------

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--	----------	---------------

- 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification \$130 fee (no small entity discount)

Fees Paid (\$)

Other (e.g., late filing surcharge): Petition to revive unintentionally abandoned application

\$750.00

SUBMITTED BY

Signature

Registration No. 38,710
(Attorney/Agent)


Telephone 858-724-0375

Name (Print/Type) David R. Preston

Date 1/17/06

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (12-04v2)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 750.00

Complete if Known

Application Number	09/831,621
Filing Date	May 10, 2001
First Named Inventor	BAUM et al.
Examiner Name	To be determined
Art Unit	To be determined
Attorney Docket No.	NEU-00119.P.1

METHOD OF PAYMENT (check all that apply)☒ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☐ Deposit Account Deposit Account Number: 501321 Deposit Account Name: David R. Preston & Assoc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity Fee (\$)
50	25

Each independent claim over 3 (including Reissues)

200	100
-----	-----

Multiple dependent claims

360	180
-----	-----

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims

Fee (\$)	Fee Paid (\$)
----------	---------------

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
- 100 = _____	/ 50 = _____	(round up to a whole number) x _____	= _____	

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Fees Paid (\$)

Other (e.g., late filing surcharge): Petition to revive unintentionally abandoned application

\$750.00

SUBMITTED BY

Signature

Registration No. 38,710
(Attorney/Agent)

Telephone 858-724-0375

Name (Print/Type) David R. Preston

Date 1/17/06

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



#10

Patent

Docket Number: NEU-00119.P.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)

BAUM et al.)

Application No.: 09/831,621)

Filed: May 10, 2001)

For: NOVEL DNAs AND)
POLYPEPTIDES)

Examiner: To be determined

Art Unit: To be determined

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED

JAN 24 2006

OFFICE OF PETITIONS

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS**PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY UNDER 37 C.F.R. § 1.137 (b)**

Sir:

Applicants are responding to the Notification of Missing Requirements mailed on August 13, 2001, notifying Applicants that a proper Oath or Declaration along with computer readable form of the Sequence Listing must be provided. Applicants submit herewith, a previously signed copy of the Declaration along with a copy of the Sequence Listing in paper copy and computer readable format, along with a Statemen under 35 C.F.R. § 1.821. Please note that the Declaration was signed in 2001 and a new Power of Attorney was accepted by the USPTO in 2005 as shown in the enclosed Notice of Acceptance of Power of Attorney.

Applicants also submit herewith, a Petition for Revival of an Application for Patent Abandoned Unintentionally under 37 CFR §1.137(b), along with a fee of \$750.00.

Please apply any charges not covered, or any credits, to **Deposit Account 501321** in the name of **David R. Preston & Associates** having **Customer No.: 24232**.

Date: Jan 17, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'D. Preston', written over a horizontal line.

David R. Preston
Reg. No. 38,710

David R. Preston & Associates, A.P.C.
12625 High Bluff Drive
Suite 205
San Diego, CA 92130

Telephone: 858.724.0375
Facsimile: 858.724.0384



Case No.: 98,664-B

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

RECEIVED

JAN 24 2006

OFFICE OF PETITIONS

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel DNAs and Polypeptide

the specification of which is attached hereto unless the following space is checked:

- ☒ was filed on May 10, 2001 (I.A. Filing Date: November 10, 1999) as United States Application Serial Number 09/831,621.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s):

	<u>Number</u>	<u>Country</u>	<u>Day/Month/Year Filed</u>
1.			
2.			

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

	<u>Application Number</u>	<u>Filing Date</u>
1.	60/107,821	November 10, 1998
2.		

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

	<u>Application Number</u>	<u>Filing Date</u>	<u>Status: patented, pending, abandoned</u>
1.	PCT/US99/26788	November 10, 1999	Abandoned
2.			

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and I direct that all correspondence be addressed to that Customer Number.

Customer Number: **020306**

Principal attorney or agent: Roger P. Zimmerman

Telephone number: 312-913-0001

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Peter Robert Baum

Inventor's signature: Peter Robert Baum

Date: 10.3.2001

Residence: Seattle, Washington

Citizenship: United States of America

Post Office Address: 6027 34th Avenue N.E., Seattle, Washington 98115

Full name of second joint inventor: Robert Finley DuBose

Inventor's signature: Robert Finley DuBose

Date: 10-2-2001

Residence: Bellevue, Washington

Citizenship: United States of America

Post Office Address: 6151 156th Place Southeast, Bellevue, Washington 98006

Full name of third joint inventor: John E. Sims

Inventor's signature: John E. Sims

Date: 10-2-2001

Residence: Seattle, Washington

Citizenship: United States of America

Post Office Address: 4207 43rd Avenue Northeast, Seattle, Washington 98105

Full name of fourth joint inventor: Adel Youakim

Inventor's signature: Adel Youakim


Date: 10-2-2001

Residence: Seattle, Washington

Citizenship: Canada

Post Office Address: 1940 Bonair Dr. S.W., Seattle, Washington 98116

Full name of fifth joint inventor: Karl W. Hasel

Inventor's signature: 


Date: Sept 4th, 2001

Residence: Solana Beach, California

Citizenship: Switzerland

Post Office Address: 247 South Nardo Avenue, Solana Beach, California 92075

Full name of fourth joint inventor: Brian S. Hilbush

Inventor's signature: 

Date: September 4th, 2001

Residence: San Diego, California

Citizenship: United States of America

Post Office Address: 5690 Willowmere Lane, San Diego, California 92130

4628



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831621	BAUM P	98,664-B
INTERNATIONAL APPLICATION NO.		
PCT/US99/26788		
- I.A. FILING DATE -		PRIORITY DATE
10 NOV 99		10 NOV 98

ROGER P ZIMMERMAN
MCDONNELL BOEHNNEN HULBERT & BERGHOFF
300 SOUT WACKER DRIVE
SUITE 3200
CHICAGO, IL 60606

DATE MAILED: 13 AUG 2001

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

1. The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as ☐ a Designated Office (37 CFR 1.494) ☒ an Elected Office (37 CFR 1.495):
- | | |
|---|---|
| <input checked="" type="checkbox"/> U.S. Basic National Fee. | <input checked="" type="checkbox"/> Indication of Small Entity Status. |
| <input checked="" type="checkbox"/> Copy of the international application. | <input type="checkbox"/> Translation of the international application into English. |
| <input type="checkbox"/> Oath or Declaration of inventor(s). | <input type="checkbox"/> Translation of Article 19 amendments into English. |
| <input type="checkbox"/> Copy of Article 19 amendments. | <input type="checkbox"/> Other: |
| <input type="checkbox"/> Priority Document. | |
| <input type="checkbox"/> The International Preliminary Examination Report in English and its Annexes, if any. | |
| <input type="checkbox"/> Translation of Annexes to the International Preliminary Examination Report into English. | |
2. ☐ Applicant has requested early processing under 35 U.S.C. 371(f) but has not filed the following indicated items and/or the indicated items in paragraph 3 below. The Basic National Fee and the copy of the international application must be filed prior to 20 or 30 months from the priority date to avoid abandonment.
- ☐ U.S. Basic National Fee. ☐ Copy of the international application.
3. The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:
- ☐ a. Translation of the application into English. A processing fee will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current translation is defective for the reasons indicated on the attached Notice of Defective Translation.
- ☐ b. Processing fee for providing the translation of the application and/or the Annexes later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(f)).
- ☒ c. Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), properly identifying the application (preferably by the International application number and international filing date). A surcharge will be required if submitted later than the appropriate 20 or 30 months from the priority date.
- ☐ The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) for the reasons indicated on the attached PCT/DO/EO/917.
- ☒ d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)).
4. Additional claim fees of \$ _____ as a ☐ large entity ☐ small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due (37 CFR 1.492(g)). See attached PTO-875.
5. ☒ Applicant has not submitted the required sequence listing pursuant to 37 CFR 1.821-1.825. See attached PCT/DO/EO/920.

ALL OF THE ITEMS SET FORTH IN 3(a)-3(d), 4 AND 5 ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 22 OR 32 MONTHS (where 37 CFR 1.495 applies) FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

6. If box 3a or 3c is checked, a translation of the Annexes **MUST** be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.
7. ☐ The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d)) or 30 (37 CFR 1.495(d)) months from the priority date.

Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above. (37 CFR 1.5)


A copy of this notice *MUST* be returned with this response.

Enclosed: ☐ PCT/DO/EO/917 ☐ Notice of Defective Translation
☐ PTO-875 ☒ PCT/DO/EO/920

SHELBY VIGIL, PARALEG

Telephone: 703-305-3653

FORM PCT/DO/EO/905 (March 2001)



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/831621	BAUM	P 98,664-B
INTERNATIONAL APPLICATION NO.		
PCT/US99/26788		
I.A. FILING DATE		PRIORITY DATE
10 NOV 99		10 NOV 98

ROGER P ZIMMERMAN
MCDONNELL BOEHNEN HULBERT & BERGHOF
300 SOUT WACKER DRIVE
SUITE 3200
CHICAGO, IL 60606

DATE MAILED **13 AUG 2001**

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☐ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☐ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:**

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

SHELBY VIGIL, PARALEG *SV*
Telephone: 703-305-3653



JAN 20 2006

UNITED STATES PATENT AND TRADEMARK OFFICE

NEU-119.7.1

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
09/831,621	05/10/2001	Peter R Baum	98,664-B

24232
DAVID R PRESTON & ASSOCIATES APC
12625 HIGH BLUFF DRIVE
SUITE 205
SAN DIEGO, CA 92130

CONFIRMATION NO. 6901

OC000000016385642

OC000000016385642

Date Mailed: 06/27/2005

NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 05/09/2005.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

RECEIVED

JAN 24 2006

OFFICE OF PETITIONS

JAMES E. MASON
1600 (571) 272-0539

ATTORNEY/APPLICANT COPY

RECEIVED
JUN 29 2005

BY -----



Patent
Docket Number: NEU-00119.P.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	
)	
BAUM et al.)	Examiner: To be determined
)	
Application No.: 09/831,621)	Art Unit: To be determined
)	
Filed: May 10, 2001)	
)	
For: NOVEL DNAs AND)	
POLYPEPTIDES)	
)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JAN 24 2006
OFFICE OF PETITIONS

Sir:


STATEMENT UNDER 37 C.F.R. 1.821 THROUGH 1.825

In accordance with the requirements under 37 C.F.R. 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, Applicants submit herewith a Written Sequence Listing and corresponding Computer-Readable Form Sequence Listing for the above-identified application. The information recorded in Computer Readable Form is identical to the Written Sequence Listing.

Please apply any charges not covered, or any credits, to Deposit Account 501321 in the name of **David R. Preston & Associates** having Customer No.: 24232.

Respectfully submitted,

Date: Jan 17, 2006

A handwritten signature in black ink, appearing to read 'David R. Preston', written over a horizontal line.

David R. Preston

Reg. No. 38,710

David R. Preston & Associates, A.P.C.
12625 High Bluff Drive
Suite 205
San Diego, CA 92130

Telephone: 858.724-0375
Facsimile: 858.724-0384



NEU-119.P.1, Sequence Listing
SEQUENCE LISTING

<110> Baum, Peter
DuBose, Robert
Sims, John E.
Youakim, Adel
Hasel, Karl W.
Hilbush, Brian S.

<120> Novel DNAs and Polypeptides

<130> 98664-A

<140> PCT/US99/26788

<141> 1999-11-10

<150> 60/107821

<151> 1998-11-10

<160> 33

<170> PatentIn version 3.2

<210> 1

<211> 137

<212> DNA

<213> Homo sapiens

<400> 1

ccggttaagta aacagtcaga aaattagcat gaaagcagtt tagcattggg aggaagcaca 60

gatctctaga gctgtcctgt cgctgccag gattgacctg tgtgtaagtc ccaataaact 120

cacctactca ccaaaaa 137

<210> 2

<211> 108

<212> DNA

<213> Homo sapiens

<400> 2

cggttcttga gcccagtaga tgccatttga agaaaaaat cacttgaaaa tgagacagaa 60

agaatggaaa ctaaatccta gctctaaagg caccaggctg attaaaaa 108

<210> 3

<211> 306

<212> DNA

<213> Homo sapiens

<400> 3

cggcttcagc agtatcgtgc caaagcagaa ctagctcgat ctaccagacc ccaggcctgg 60

gttccaaggg aaaaattgcc cagaccactc accagcagtg cttcagctat tcgtaaaactt 120

atgcggaaag cagaactcat ggggatcagt acagatatct ttccagtgga caattcagat 180

actagttcta gtgtggatgg aaggagaaaa cataagcaac cagctctcac tgcagatttt 240

gtaaattatt attttgagag aaatatgccc atgattcaaa ttcaggaaaa tatggctgaa 300

NEU-119.P.1, Sequence Listing

caaaaa

306

<210> 4
<211> 366
<212> DNA
<213> Homo sapiens

<400> 4
cggccatgtg gytgctcggc cctkggttgc tcgcttgctg tgcaagacat tagcccttta 60
gttatgagcc tgtgggaact tcaggggttc ccagtgggga gagcagtggc agtgggaggg 120
atctgggggc caaaggtcag tggcaggggg tatttcagta ttatacaact gctgtggcca 180
gacttgata ctggctgaat atcagtgtg tttgtaattt ttactttga gaaccaacat 240
taattccata cgaatcaagt gttttgtaac tgctattcat ttattcagca aatatttatt 300
gatcatctct tctccataag atagtgtgat aaacacagtc atgaataaag ttatttccac 360
caaaaa 366

<210> 5
<211> 324
<212> DNA
<213> Homo sapiens

<400> 5
cggccgacac tgggcttttt atgagagtga cagattacta ggacctcatt atgtggtaga 60
agtaatgtag gggaaatggc gattatcttt ttttaaagc aatagctgtt gtatatcaat 120
gataaatgaa aaattagtta ttcttgtaa ttgaagaaag aatggttatc atagagggta 180
gttcaagtaa aagaaccagg gctgggtgtg gtggctcacg ttctgtagtc cctgtacttt 240
gggaggccaa ggcagatgga tctcttgagg ccaggagttc gagaccagcc tgaccaacat 300
ggcgagaccg tgtctcccca aaaa 324

<210> 6
<211> 398
<212> DNA
<213> Homo sapiens

<400> 6
cggtgatga cagcccacgg gcggcacagt cacttctgcc tgttgctctg acaccaaccc 60
aggcagctct gctgtggctt ctctgggct ctggcattag ttggtctgtg tcacattgtc 120
agaacaggtg gcctgtgtgg tgccatcgag tccctgctgg tcccccttgt cctgggaggg 180
tcacccattg cccaaggaag tgcattccacc tggcaggtga cctggaggag tagcttcccc 240
gaggaccccc aggcttggcc tgtgattgcg caaacccaca tttcctaagc aactggaca 300
cccttcgagt gtgggtttta acatccctgt gagattgaat acttgtgcca cacatgtcac 360
aaaagagtat ggaaataaaa gaaaatttat ccgaaaaa 398

NEU-119.P.1, Sequence Listing

<210> 7
 <211> 113
 <212> DNA
 <213> Homo sapiens

<400> 7
 ccggtctatg gcattaaccc tcaacttaact tttcagcctg ccagcctgcc ctatggattt 60
 cggacttgcc agccacacaa ttccttaaaa taaatctctc cgtctcataa aaa 113

<210> 8
 <211> 379
 <212> DNA
 <213> Homo sapiens

<400> 8
 ccgggagctg tgaaggggaac gtgagggggc ggcgtagtgg agacccacgg caggcctgaa 60
 gaagagcggc ggccgagccc gccttcccctg caccatgctc atagaggatg tggatgccct 120
 caagtcctgg ctggccaagt tactggagcc gatatgtgat gctgatcctt cagccttagc 180
 caactatggt gtagcactgg tcaagaagga caaacctgag aaagaattaa aagccttttg 240
 tgctgatcaa ctgatgtct ttttacaaaa agaaacttca ggttttgtgg acaaactatt 300
 tgaaagtctc tatactaaga actaccttcc acttttggaa ccagtaaagc ctgagccaaa 360
 accactagcc caagaaaaa 379

<210> 9
 <211> 170
 <212> DNA
 <213> Homo sapiens

<400> 9
 cggctgcctg cttttttttc tgatccagac cctcggcacc tgctacttac caactggaaa 60
 attttacgca tcccatgaag cccagataca caaaattcca ccccatgatc aagaatcctg 120
 ctccactaag aatggtgcta aagtaaaaact agtttaataa gccctaaaaa 170

<210> 10
 <211> 60
 <212> DNA
 <213> Homo sapiens

<400> 10
 ccgggatatc gccactgcac tccagcctgg gtgacggagc gagactccgt ctcagaaaaa 60

<210> 11
 <211> 569
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature

NEU-119.P.1, Sequence Listing

<222> (527)..(527)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (542)..(542)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (549)..(549)
<223> n is a, c, g, or t

<220>
<221> misc_feature
<222> (556)..(556)
<223> n is a, c, g, or t

<400> 11	
tcaatcctgg gcggcgacaa gacagctcta gagatctgag cttcctccca atgctaaact	60
gctttcatgc taattttctg actgtttact taccgggtaa gagcgatggg actgttttca	120
ttggttggtt ctcacatact ctctgggaag tttgggttct cagggacacc tgctcctcag	180
ctggggacca tggccatggc ccaccacctg cccttcagtg ttcaagcagg ggacatgcac	240
ccttttagtaa cctggagggg acccatcaca tgacaaccac cccaacgacc atcatcagga	300
agccgctgcc tgactgagat atgccccag gaggacaagg gagagtggat gctggaaaga	360
cagggcaggg gaccatcacc agggaaagac ttatttcttc ggaggacatt gaacctgggg	420
ctgggtctgt agtggagccg ctgtttcttc tctgtatcc aactgttcta actcttgggc	480
tttctccatt ttcagctctt tcttttctctg gccttctcat tgctggntcc ttcaagcctc	540
cncctatnc ttccgncaat atattcttt	569

<210> 12
<211> 612
<212> DNA
<213> Homo sapiens

<400> 12	
cggcgacaag acagctctag agatctgagc ttcctcccaa tgctaaactg ctttcatgct	60
aattttctga ctgtttactt accgggtaag agcgatggga ctgttttcat tgggttggtc	120
tcacatactc tctgggaagt ttgggttctc agggacacct gctcctcagc tggggaccat	180
ggccatggcc caccacctgc ctttcagtgt tcaagcaggg gacatgcacc ctttagtaac	240
ctggagggga cccatcacat gacaaccacc ccaacgacca tcatcaggaa gccgctgcct	300
gactgagata tgcccccagg aggacaagg agagtggatg ctggaaagac agggcagggg	360
accatcacca gggaaagact tcattcttcg gaggacattg aacctggggc tgggtctgta	420
gtggagccgc tgtttcttct cctgtatcca actgttctaa ctcttgggct ttctccattt	480
tcagctcttt cttttcctgg ctttctcatt gctggttcct tcaagcctcc tctctattct	540

NEU-119.P.1, Sequence Listing

tccgtcaata tattcttttt tttttttttt ttttgaaatg gagtctcgct ctgtcaccca 600
agctggagtg ca 612

<210> 13
<211> 618
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (613)..(613)
<223> n is a, c, g, or t

<400> 13
cacgagctgt ctggttatta tacagacgca taactggagg tgggatccac acagctcaga 60
acagctggat cttgctcagt ctctgccagg ggaagattcc ttggaggagg ccctgcagcg 120
acatggaggg agctgctttg ctgagagtct ctgtcctctg catctggatg agtgcacttt 180
tccttggtgt gggagtgagg gcagaggaag ctggagcgag ggtgcaacaa aacgttccaa 240
gtgggacaga tactggagat cctcaaagta agcccctcgg tgactgggct gctggcacca 300
tggaccaga gagcagtatc ttatttgagg atgccattaa gtatttcaag gaaaaagtga 360
gcacacagaa tctgtactc ctgtgactg ataatgaggc ctggaacgga ttcgtggctg 420
ctgtgaact gccaggaat gaggcagatg agctccgtaa agctctggac aaccttgcaa 480
gacaaatgat catgaaagac aaaaactggc acgataaagg ccagcagtac agaaactggt 540
ttctgaaaag agtttctctg ggtgaaaaag taagcttgag gataacataa gaaagcttcc 600
gtgcccttgc aanatggg 618

<210> 14
<211> 1044
<212> DNA
<213> Homo sapiens

<400> 14
gaatttaata cgactcacta tagggaattt ggccctcgag gccaagaatt cggcacgagg 60
caacaacaac aacaaaaaaa aactgaacat ctccatatta ctgacaccca attcaagaaa 120
caaaatatta cagccccctt caggatattc ctgggggtctc ttccatctct actaaccctt 180
gactacaaac agcctccacc tatttcacct gacattgtac tttatgaaag cagcagttct 240
cagatggggc tattttgccc cctggggaca ttagggagta tctggagaca ctgaggggtg 300
tgtctacttg gggggagttg tgttactgca tccagtgagt ccagggatcc agggatgccg 360
ctcaacatcc tgaaatgcac aggggaacccc cacacataga acagagaaat tgctgagcca 420
aaatgtcagc agtgtcacag ctgacaccct gatatacaca ctatcacaca gtatctgctc 480

NEU-119.P.1, Sequence Listing

tttcgggctc aggatctttt tcattcta	catctcatag gaaacagaaa tgtcatttag	540		
aggtaggtac agtccacaac aaagaagaac	ctgagttttt tttttttttt taatcagcct	600		
ggtgccttta gagctaggat ttagtttcta	ttctttctgt ctcattttca agtgattttt	660		
ttcttcaa	at ggcatctact gggctcaaga actggagatc	cccacaaagc tgagattcac	720	
atgggaattt	tgtacacacc cacacaggta tacacttcca	tttaca	tgca gacatccacc	780
cacagataca	cacatccgga gaccaagaca gaacgcaaac	tgccccataa	aagcacggtt	840
ccccaaacag	gagaaacgca ccattcactc cagggaggta	tctatttg	tt taattcagcc	900
tctgatagtc	aggctgttgc caagcccagc tctgaaactc	ttcccc	tcta ggaaagaaag	960
atggattttt	tctttactca agaatataga tctaaaaaaa	aaaaaaaa	aagttggcgg	1020
ccgcaagctt	attcccttta gtga			1044

<210> 15
 <211> 2577
 <212> DNA
 <213> Homo sapiens

<400> 15	ggtaccgggc cccccctcga ggtcgacggt	atcgataagc ttgatatcga attcgcggcc	60
	gctgagaaat taactccccg gggccgcccgg	gttgactgcg ctgcctgggc cggaggctctt	120
	ctccggccag ggagcgctgt ggggaaggggc	tcgagcggcc agggccaggc gaggccgggg	180
	gggcgggggg ttaggggacc gcggggctac	tcttgggagc gcccctgtcc ggctggctgc	240
	gcgccggttt taaatagcat ctttcggact	tgtcttcgcg gccccagtcc cgcacctcg	300
	cgctgcctgg gctcctgcag cctctcccta	agtcttctcc aaacgaccac ctcacggatt	360
	ccttatggat cgcagctcca agaggaggca	ggtgaagcct ttggcagctt ctctgctgga	420
	agctcttgat tatgatagtt cagatgacag	tgattttaaa gttggagatg cctcaggact	480
	cgctgattct tgagaagagt caaaactgga	gctctcaaaa aatggaccat attctgattt	540
	gctgtgtttg tctgggagat aatagtgagg	acgctgatga aataattcag tgtgacaatt	600
	gtggcattac agtccatgaa ggttgttatg	gagttgatgg agagagtgac tctattatga	660
	gttcagcttc tgaaaactcc actgaacctt	ggttttgtga tgcctgtaaa tgtggtgttt	720
	ctcctagctg tgaactgtgt cctaatacag	atgggaatttt caaggagaca gatgctggaa	780
	gatgggttca tattgtttgt gccctgtatg	ttcctggagt agcctttgga gatattgaca	840
	aattacgacc agtaacacta acggaaatga	actattccaa atatggtgcc aaggagtgt	900
	gcttttgtga agaccctcgc tttgctagaa	ctgggggtttg cattagctgt gatgcaggga	960
	tgtgcagagc ctatttccat gtgacctgtg	ctcaaaagga aggtctgctt tcagaggcag	1020
	cggcggaaga ggatatagca gatccattct	ttgcttattg taagcaacat gcagataggt	1080

NEU-119.P.1, Sequence Listing

tagacagaaa	gtggaagaga	aaaaactact	tggctctaca	gtcctattgt	aaaatgtctt	1140
tgcaagagag	agagaagcaa	ctatcaccag	aagcacaggc	aaggatcaat	gcccggcttc	1200
agcagtatcg	tgccaaagca	gaactagctc	gatctaccag	accccaggcc	tgggttccaa	1260
gggaaaaatt	gcccagacca	ctcaccagca	gtgcttcagc	tattcgtaaa	cttatgcgga	1320
aagcagaact	catggggatc	agtacagata	tctttccagt	ggacaattca	gatactagtt	1380
ctagtgtgga	tggaaggaga	aaacataagc	aaccagctct	cactgcagat	tttgtgaatt	1440
attattttga	gagaaatatg	cgcattgattc	aaattcagga	aaatatggct	gaacaaaaga	1500
atataaaaga	taaattagag	aatgaacaag	aaaagcttca	tgtagaatat	aataagctat	1560
gtgaatcttt	agaagaacta	caaaacctga	atggaaaact	tcgaagtga	ggacaaggaa	1620
tatgggcttt	actaggcaga	atcacagggc	agaagttgaa	tataccggca	attttgcgag	1680
caccaagga	gagaaaacca	agtaaaaaag	aaggaggcac	acaaaagaca	tctactcttc	1740
ctgcagtact	ttatagtgtg	gggatttgta	agaagaacca	tgatcagcat	cttcttttat	1800
tgtgtgatac	ctgtaaacta	cattaccatc	ttggatgtct	ggatcctcct	cttacaagga	1860
tgccaagaaa	gacaaaaaac	agttattggc	agtgtctcga	atgtgaccag	gcagggagca	1920
gtgacatgga	agcagatatg	gccatggaaa	ccctaccaga	tggaaccaa	cgatcaagga	1980
ggcagattaa	ggaaccagtg	aaatttggtc	cacaggatgt	gccaccagaa	cccaagaaga	2040
ttccgataag	aaacacgaga	accagaggac	gaaaacgaag	cttcgttcct	gaggaagaaa	2100
aacatgagga	aagagttcct	agagagagaa	gacaaagaca	gtctgtgttg	caaaagaagc	2160
ccaaggctga	agattttaaga	actgaatgtg	caacttgcaa	gggaactgga	gacaatgaaa	2220
atcttgtcag	gtgtgatgaa	tgcagactct	gctaccattt	tggtgtttg	gatcctcctt	2280
tgaaaaagtc	tcctaaacag	acaggctacg	gatggatatg	tcaggaatgt	gattcttcat	2340
cttccaagga	agatgaaaat	gaagctgaaa	gaaaaaatat	atctcaggag	ctcaacatgg	2400
aacagaaaaa	tccaaagaaa	taaaagattt	tctgtagtgt	ttttgaaaag	tttgcagctt	2460
atgtaatagc	agataaaaatt	tctaattgta	aaatgttaaa	ttgagcggcc	gcgaattcct	2520
gcagcccggg	ggatccacta	gttctagagc	ggccgccacc	gcggtggagc	tccagct	2577

<210> 16
 <211> 2065
 <212> DNA
 <213> Homo sapiens

<400> 16	
attaaccctc	actaaagggg
acaaaagctg	gagctccacc
gcggtggcgg	ccgctctaga
	60
actagtggat	cccccgggct
gcaggaattc	ggcacgaggt
gcgcggctgc	aacggcagcc
	120
gcgggaagct	cgggccggca
gggtttcccc	gcacgctggc
gcccagctcc	cggcgcggag
	180

NEU-119.P.1, Sequence Listing

gccgctgtaa gtttcgcttt ccattcagtg gaaaacgaaa gctgggcggg gtgccacgag	240
cgcgggggcca gaccaaggcg ggcccggagc ggaacttcgg tcccagctcg gtccccggct	300
cagtcccgac gtggaactca gcagcggagg ctggacgctt gcatggcgct tgagagattc	360
catcgtgcct ggctcacata agcgccttcct ggaagtgaag tcgtgctgtc ctgaacgcgg	420
gccaggcagc tgcggcctgg gggttttgga gtgatcacga atgagcaagg cgtttgggct	480
cctgaggcaa atctgtcagt ccatcctggc tgagtcctcg cagtccccgg cagatcttga	540
agaaaagaag gaagaagaca gcaacatgaa gagagagcag cccagagagc gtcccagggc	600
ctgggactac cctcatggcc tggttgggtt acacaacatt ggacagacct gctgccttaa	660
ctccttgatt cagggtgttcg taatgaatgt ggacttcacc aggatattga agaggatcac	720
ggtgcccagg ggagctgacg agcagaggag aagcgtccct ttccagatgc ttctgctgct	780
ggagaagatg caggacagcc ggcagaaagc agtgcgggccc ctggagctgg cctactgcct	840
gcagaagtgc aacgtgccct tgtttgtcca acatgatgct gcccaactgt acctcaaact	900
ctggaacctg attaaggacc agatcactga tgtgcacttg gtggagagac tgcaggccct	960
gtatatgata cgggtgaagg actccttgat ttgcgttgac tgtgccatgg agagtagcag	1020
aaacagcagc atgctcacc tcccactttc tctttttgat gtggactcaa agcccctgaa	1080
gacactggag gacgccctgc actgcttctt ccagcccagg gagttatcaa gcaaaagcaa	1140
gtgcttctgt gagaactgtg ggaagaagac ccgtgggaaa caggctctga agctgacca	1200
tttggcccag accctgacaa tccacctcat gcgattctcc atcaggaatt cacagacgag	1260
aaagatctgc cactccctgt acttccccca gagcttggat ttcagccaga tccttccaat	1320
gaagcgagag tcttgtgatg ctgaggagca gtctggaggg cagtatgagc tttttgctgt	1380
gattgcgcac gtgggaatgg cagactccgg tcattactgt gtctacatcc ggaatgctgt	1440
ggatggaaaa tggttctgct tcaatgactc caatatttgc ttggtgtcct gggaaagacat	1500
ccagtgtacc tacggaaatc ctaactacca ctggcaggaa actgcatatc ttctggttta	1560
catgaagatg gagtgctaata ggaaatgccc aaaaccttca gagattgaca cgctgtcatt	1620
ttccatttcc gttcctggat ctacggagtc ttctaagaga ttttgcaatg aggagaagca	1680
ttgttttcaa actatataac tgagccttat ttataattag ggatattatc aaaatatgta	1740
accatgaggc cctcagggtc ctgatcagtc agaattggatg ctttcaccag cagaccggc	1800
catgtggctg ctcggtcctg ggtgctcgct gctgtgcaag acattagccc tttagttatg	1860
agcctgtggg aacttcaggg gttcccagtg gggagagcag tggcagtggg aggcattctg	1920
gggccaagg tcagtggcag ggggtatttc agtattatac aactgctgtg accagacttg	1980
tatactggct gaatatcagt gctgtttgta atttttcact ttgagaacca acattaattc	2040
catatgaaaa aaaaaaaaaa aaaaa	2065

NEU-119.P.1, Sequence Listing

<210> 17
 <211> 1588
 <212> DNA
 <213> Homo sapiens

<400> 17
 gcggccgctc tagaactagt ggatcccccg ggctgcagga attcgcggcc gctaaatgaa 60
 ctcccataag agtctacaca ccatagaact cataccagga atcacaaagt ctctaaatTT 120
 ccaaagttaa ctggaaatat tacaaactgc agaataattc caggccaaaa tatgttaaAT 180
 tcataacatg atgtatatca aaggaaaaaa ggacatgtgg aaatgacaca ttatcttcag 240
 tgtataaaat attcattttat gtgaagtttc ttggaaaggc tacactacta ttactggttt 300
 ccgtctgatg tttagatctt gttgatttta tgcttttctt acaggccttt cattatgatc 360
 tttgggaagg aatcaataaa atgatagggc ctacttcatt aggtgtgggt cattcctatt 420
 catgctccct ggaagaacaa gaatgctgaa ttttgaaatt taatattgta tgaattagca 480
 tcagggagag gtggagaaaa atacaaaact aaaagtcatg cttatttgtt tcagtgtgcc 540
 cttctccaga gggccactgg cttataggaa aggattgctg ctctaccagt tgaccaggag 600
 atggcacgcc aggacattaa gacactggag ttttgtttcg tttttttttt tttttttgag 660
 atggagtctc gctctcttga caggcaggag tacagtgggt cgatctcggc tcttgcaaaa 720
 ctccgcctcc cgggttcaag tgattctcct gcctcggcct cccgagtagc tgggactaca 780
 ggcgtgtgcc accacccccca gctaactttt gtatttttag tagagacagg gtttcaccat 840
 gttggccagg atggtctcaa tctcttgacc tcatgatccg cccgcctccg ctttccaaag 900
 tgctgggatt acaggcgtga gccagtgtgc ccggccgaca ctgggctttt tatgagagtg 960
 acagattact aggacctcat tatgtggtag aagtaatgta ggggaaatgg cgattatctt 1020
 tttttaaaag caatagctgt tgtatatcaa tgataaatga aaaattagtt attcttgtaa 1080
 attgaagaaa gaatggttat catagagggt agttcaagta aaagaaccag ggctgggtgt 1140
 ggtggctcac gttctgtaat ccctgtactt tgggaggcca aggcagatgg atctcttgag 1200
 gccaggagtt cgagaccagc ctgaccaaca tggcaaaacc gtgtctctac aaaaaataca 1260
 aaaattagcc ggacatcgtg gtagatgcct gtagtctcag atattcagga gaccgagggg 1320
 aaaatcactt gaacccgggg gacggagggt gcagtgaagt gagatcgcac cactgctcgc 1380
 cagcctgggc aacagagtga gactctgcct caaaaaaaaa ccaaaccaaa ccaaagaacc 1440
 agaatagcat gtgcacatat acacagacgt ttcacaactg gcattatggt ttgctactgt 1500
 tttatttaca atgtatcaca agttttatgc ttttaataaaa tttaatcata acttcaaaaa 1560
 aaaaaaaaaa aaaaagcggc cgcgaaatt 1588

NEU-119.P.1, Sequence Listing

<210> 18
 <211> 2173
 <212> DNA
 <213> Homo sapiens

<400> 18
 gcggccgctc ttttaccag tggcacaac tggcacaaca caggatttat actggagagc 60
 aacctcaca atgtaatgaa agtggaagg ctttttatca aatgtccttg tctttgggg 120
 catgagaaaa ttcatacaga atctattaaa aatgtactaa acatggaaag acctttaagc 180
 aacagtgatg tgatgaagg ggtagttttt taaatgaact ccataagag tctacacacc 240
 atagaactca taccaggaat cacaagtct ctaaatttcc aaagttaact ggaaatatta 300
 caaactgcag aataattcca ggccaaaata tgtaaattc ataacatgat gtatatcaaa 360
 ggaaaaaagg acatgtggaa atgacacatt atcttcagtg tataaaatat tcatttatgt 420
 gaagtttctt ggaaaggcta cactactatt actggtttcc gtctgatgtt tgagatctgt 480
 tgattttatg cttttcttac aggcctttca ttatgatctt tgggaaggaa tcaataaaat 540
 gatagggcct acttcattag gtgtggttca ttcctattca tgctcgcggc cgctctagaa 600
 ctagtggatc ccccgggctg caggaattcg cgccgctaa atgaactccc ataagagtct 660
 acacaccata gaactcatac caggaatcac aaagtctcta aatttccaaa gttaactgga 720
 aatattacaa actgcagaat aattccaggc caaaatatgt taaattcata acatgatgta 780
 tatcaaagga aaaaaggaca tgtggaaatg acacattatc ttcagtgtat aaaatattca 840
 tttatgtgaa gtttcttggg aaggctacac tactattact ggtttccgtc tgatgtttga 900
 gatctgttga ttttatgctt ttcttacagg cttttcatta tgatctttgg gaaggaaatca 960
 ataaaatgat agggcctact tcattagggtg tggttcattc ctattcatgc tccctggaag 1020
 aacaagaatg ctgaattttg aaatttaata ttgtatgaat tagcatcagg gagagggtga 1080
 gaaaaataca aaactaaaag tcatgcttat tgtgttcagt gtgcccttct ccagagggcc 1140
 actggcttat aggaaaggat tgctgctcta ccagttgacc aggagatggc acgccaggac 1200
 attaagacac tggagttttg tttcgttttt tttttttttt ttgagatgga gtctcgctct 1260
 cttgacaggc aggagtacag tggtgcgatc tcggctcact gcaaactccg cctccccggg 1320
 tcaagtgatt ctctgcctc ggccctccga gtagctggga ctacaggcgt gtgccaccac 1380
 cccagctaa cttttgtatt tttagtagag acagggtttc accatgttgg ccaggatggt 1440
 ctcaatctct tgacctcatg atccgccccg ctccgccttc caaagtgctg ggattacagg 1500
 cgtgagccag tgtgcccggc cgacactggg ctttttatga gagtgcaga ttactaggac 1560
 ctcatatgt ggtagaagta atgtagggga aatggcgatt atcttttttt aaaagcaata 1620
 gctgttgtat atcaatgata aatgaaaaat tagttattct tgtaaatgga agaaagaatg 1680
 gttatcatag agggtagttc aagtaaaaga accagggctg ggtgtggtgg ctacggttct 1740

NEU-119.P.1, Sequence Listing

gtaatccctg tactttggga ggccaaggca gatggatctc ttgaggccag gagttcgaga	1800
ccagcctgac caacatggca aaaccgtgtc tctacaaaaa atacaaaaat tagccggaca	1860
tcgtggtaga tgcctgtagt ctcagatatt caggagaccg aggggaaaaat cacttgaacc	1920
cgggggacgg aggttgcagt gagctgagat cgcaccactg ctcgccagcc tgggcaacag	1980
agtgagactc tgcctcaaaa aaaaaccaa ccaaaccaaa gaaccagaat agcatgtgca	2040
catatacaca gacgtttcac aactggcatt atgttttgct actgttttat ttacaatgta	2100
tcacaagttt tatgctttaa taaaatttaa tcataacttc aaaaaaaaaa aaaaaaaaaa	2160
gcggccgcga att	2173

<210> 19
 <211> 2410
 <212> DNA
 <213> Homo sapiens

<400> 19 gaattcggca cgaggaaaac atttgcccct tgcagaagat cacccttagt tcttcctcgg	60
aagagtatca gaaggtctgg aacctcttta accgcacgct gcctttctac tttgttcaga	120
agattgagcg agtacagaac ctggccctct gggagagtcta ccagtgggtgc gttggggctc	180
gctcttggtg ggctgggtgac tctgtccctt cacaccactg gctgggtgcc acatgtggcc	240
cgggtttcca ggaaaagcag agcggcagtt agggctgcca tgtgctggga gctgtgtgtc	300
tgctctcctt cgtccgctcc cccagggcag tgtggtagca catcccattg tagagatgag	360
ggcaccgagg cttcctggag cataccacct ggtcccgttc atgagtgggtg gcaaagctag	420
cactctcact tgtccattct gccttcctgg agaccagtgg gatgggtcag tacagcccac	480
cacaccatta gccccaggaa cataaggctg tggctagaca gcaggggtct caggttcata	540
catgaggact ggcttgtcct tgagcaccca ctcacctgtc tatgtgggga ggaatcctac	600
aataggtcac catggcaggc tgggtcttgc tgacctgtcc ccagatgggg ttggggtagt	660
gtaatgtgta ctctgtgcac agtgatgaag tctgggaatg ggagagggga gaaggatggg	720
caccactga ccagcagcct gaaaattcct acagcatccc agggctcagc tccatgcagg	780
agcaagggtg ggggtggggtt gggggaaatg ttaccattt tccaagggt gctctgcttt	840
tggagtccag ggaaccgctg ctgtctggag ctgtggaggg agggttttca cccagctccc	900
acgatcccc ttcttttcca caccctggct tgtggctgga gccttacagg cctagtcagg	960
gtagcctgtg acctgcgtct cttgggtcca ggacactttt ggaattttgg aaaaatgtgt	1020
tgttttgcat caggccggct gtatttggtg gccggcacac tctgccccca gcacacattc	1080
ttctgtgatt ctaggcaaaa aggacagatg cagaagcaga acggagggaa ggccgtggac	1140
gagcggcagc tgttccacgg caccagcgcc atttttgtgg acgccatctg ccagcagaac	1200

NEU-119.P.1, Sequence Listing

tttgactggc gggctctgtgg tgttcatggc acttcctacg gcaaggggag ctactttgcc	1260
cgagatgctg catattccca ccactacagc aaatccgaca cgcagaccca cacgatgttc	1320
ctggccccggg tgctgggtggg cgagttcgtc aggggcaatg cctcctttgt ccgtccgccg	1380
gccaaggagg gctggagcaa cgccttctat gatagctgcg tgaacagtgt gtccgacccc	1440
tccatctttg tgatctttga gaaacaccag gtctaccag agtatgtcat ccagtacacc	1500
acctcctcca agccctcggc cacaccctcc atcctgctgg ccttgggctc cctgttcagc	1560
agccgacagt gagcgcacag gagtgttcca ggcctttcac ctgctctgcc ttgaaatggc	1620
tatttggggc tttccttttc tttttaaaca gaaactttta atgaactgtt ctcttaacat	1680
tgacctctca atgaagttat gttcttaatc tcttgctaata atgattttt acttttaagt	1740
cacttttggg ttcactagtg gattaaccag aagtgattgt agttgagtcc agttttgctt	1800
tttaataatg tgttgaagtt ttagttttta ctctttgttg actttgctgc ttattggcac	1860
cagggacaga gtttctagat acaattttat ggattgggtt taatttttat gagtttgtct	1920
ctgcagtgat tcggtttctc agagtctcat ggcacatag tttttccaga atgacacagt	1980
agccaccggc ggatgacagc ccacgggcgg cacagtcact tctgcctgtt gctctgacac	2040
caaccaggc agctctgctg tggcttctcc tgggctctgg cattagttgg tctgtgtcac	2100
attgtcagaa cagggtggctg ctgtgtgggtg ccatcgagtc cctgctgggt ccccttgctc	2160
tgggagggc acccattgcc caaggaagtg catccacctg gcagggtgacc tggaggagta	2220
gcttccccga ggacccccag gcttggcctg tgattgcgca aaccacatt tcctaagcac	2280
actggacacc cttcgagtgt gggttttaac atccctgtga gattgaatac ttgtgccaca	2340
catgtcaciaa aagagtatgg aaataaaaga aaatttatcc gaaaaaaaaa aaaaaaaaaat	2400
gagcggccgc	2410

<210> 20
 <211> 1669
 <212> DNA
 <213> Homo sapiens

<400> 20	
ttgcagagct cgtttagtga accgtcagaa ttttgtaata cgactcacta tagggcggcc	60
gcgaattcgg caccaggttt cccccggctc tggcagagaa acctgggttt cgacttgtga	120
agcttgaggt tggatgtggg aattggcttg gagtcatagg cgatgagagg gacattagga	180
tattatgaag cccgtgaact caactcctga gaaggacaca gcagagcgag agaaaagatg	240
gaataaaaaag gcctacctca ttgggctcgt gtgggtgagg agaactgaag agtctgagag	300
cgcggcacga gccagaggct acggaaaaca ctgccctcct acactccacc ttggagagac	360
ccagaaaaga acaagcttca tttgtaaaaa aggaaaacaa ctgaggcaat gggggtggct	420

NEU-119.P.1, Sequence Listing

taaaggcact ctacagtgtg cagatgcctt ccacttcttc catctgccct gtctctccaa	480
gaacccctat ggccccggtc tcagaacaga gctgagtga gaaatgaaaa tctatggctc	540
tgtgtttccaa aacgatgaag aatttcaaga tgggtggcagt ggtaaaatcc ttctccagga	600
aaaatctgtc cttggcccaa tgtgtaaaca cttgctgagg aacttggaat aacttgcagt	660
gtcttgcagt attgtgaaac cagcaacttg ttcacaattc ttctgaattt cttgggaaat	720
ttgaagtgga gtacctgtac caacatgaaa tgacacgaat ttaagtgcg ctcaacaacg	780
aaaagcaaaa agaaccaaag aggaagcaac tgaaacaaca tctggatgta tttaaaaata	840
tacaatgcct ccaaaatcag gtgtcattaa tgaaaattct gaagaaatgc caccggacat	900
agccaacgca cctacgctgt tgttattcat ttcctgcttt tcacagaaaa caattttgtt	960
gcatggaaga tcgtgaactt caaagggcag aggggaaact gtcccttggc ctctaccct	1020
ccaaggcccc actttttcat caacactcct tggacgcagc agaagtatga acataatatg	1080
gtcctgaatg aggctgagtc tttgggcgca gaagacccgg gttaataaaa ataggaaggt	1140
aagaaaagaa aagaaaaatc aagacacatc ataggactaa attcctatta tttatccact	1200
caggattgac caccctttt ggccagatag ttgtaccccc atgtaccagg tgggcacatg	1260
aagacacaag aagtgtgtg atggttcatt ttgcacgtca ccttgcgtgg agtatgccaa	1320
ctcattgttt ggtcaaacac tagtctggac atggtggtaa aggtattttt tagatgagat	1380
taacgcttaa atcagtaaag caggttaccc accatactac ggggtgggccc tgtccaatca	1440
gttgaaggca ttaagaacaa agattgaggt ttcctaaaga agatggaatt ctccttgaga	1500
ctacaacata gaaaccctat ctgagtttcc agcctgttgc cctgtggaat tcaaactcag	1560
gactccggtc tatggcatta accctcactt aacttttcag cctgccagcc tgccctatgg	1620
atttcggact tgccagccac acaattcctt aaaataaatc tctccgtct	1669

<210> 21
 <211> 1025
 <212> DNA
 <213> Homo sapiens

<400> 21 atggatagtc gccacacctt tgccccctgct gcgatgaccc tgtcgccact tctgctgttc	60
ctgccaccgc tgctgctgct gctggacgtc cccacggcgg cgggtgcaggc gtccccctctg	120
caagcgtttag acttcttttg gaatgggcca ccagttaact acaagacagg caatctatac	180
ctgcgggggc ccctgaagaa gtccaatgca ccgcttgtca atgtgaccct ctactatgaa	240
gcactgtgcg gtggctgccg agccttcctg atccgggagc tcttcccaac atggctgttg	300
gtcatggaga tcctcaatgt cacgctgggtg ccctacggaa acgcacagga acaaaatgtc	360
agtggcaggt gggagttcaa gtgccagcat ggagaagagg agtgcaaatt caacaagggtg	420

NEU-119.P.1, Sequence Listing

gaggcctg	cg	tgttgatga	acttgacatg	gagctagcct	tcctgaccat	tgtctgcatg	480
gaagagttt	g	aggacatgga	gagaagtctg	ccactatgcc	tgcagctcta	cgccccaggg	540
ctgtcgccag		acactatcat	ggagtgtgca	atgggggacc	ccggcatgca	gctcatgcac	600
gccaacgccc		agcggacaga	tgctctccag	ccaccacacg	agtatgtgcc	ctgggtcacc	660
gtcaatggga		aacccttgga	agatcagacc	cagctcctta	cccttgctg	ccagttgtac	720
cagggcaaga		agccggatgt	ctgcccttcc	tcaaccagct	ccctcaggag	tgtttgcttc	780
aagtgatggc		cggtgagctg	cggagagctc	atggaaggcg	agtgggaacc	cggtgcctg	840
cctttttttt		ctgatccaga	ccctcggcac	ctgctactta	ccaactggaa	aattttatgc	900
atcccatgaa		gcccagatac	acaaaattcc	accccatgat	caagaatcct	gctccactaa	960
gaatggtgct		aaagtaaaac	tagtttaata	agcaaaaaaa	aaaaaaaaaa	aattcctg	1020
gccgc							1025

<210> 22
 <211> 1039
 <212> DNA
 <213> Homo sapiens

<400>	22						
gaattcggca		cgagggctgc	agtcgccaca	cctttgcccc	tgctgcatg	accctgtcgc	60
cacttctgct		gttcctgcca	ccgtgctgc	tgctgctgga	cgtccccacg	gcggcggctg	120
aggcgtcccc		tctgcaagcg	ttagacttct	ttgggaatgg	gccaccagtt	aactacaaga	180
caggcaatct		atacctgcgg	gggcccctga	agaagtccaa	tgcaccgctt	gtcaatgtga	240
ccctctacta		tgaagcactg	tgcggtggct	gccgagcctt	cctgatccgg	gagctcttcc	300
caacatggct		gttggatcatg	gagatcctca	atgtcacgct	ggtgccctac	ggaaacgcac	360
aggaacaaaa		tgctagtggtc	aggtgggagt	tcaagtgcc	gcatggagaa	gaggagtgc	420
aattcaacaa		ggtggaggcc	tgctgtgttg	atgaacttga	catggagcta	gccttcctga	480
ccattgtctg		catggaagag	tttgaggaca	tggagagaag	tctgccacta	tgctgcagc	540
tctacgcccc		agggtgtctg	ccagacacta	tcatggagtg	tgcaatgggg	gaccccgga	600
tgcagctcat		gcacgccaac	gcccagcgg	cagatgctct	ccagccacca	cacgagtatg	660
tgccctgggt		caccgtcaat	gggaaaccct	tggagatca	gaccagctc	cttacccttg	720
tctgccagtt		gtaccagggc	aagaagccgg	atgtctgccc	ttcctcaacc	agctccctca	780
ggagtgtttg		cttcaagtga	tggccgggtga	gctgcggaga	gctcatggaa	ggcgagtggg	840
aacccggctg		cctgcctttt	ttttctgac	cagaccctcg	gcacctgcta	cttaccact	900
ggaaaatttt		atgcatccca	tgaagcccag	atacacaaaa	ttccacccca	tgatcaagaa	960
tcctgctcca		ctaagaatgg	tgctaaagta	aaactagttt	aataagcaaa	aaaaaaaaaa	1020

NEU-119.P.1, Sequence Listing

aaaaaattcc tgcggccgc

1039

<210> 23
<211> 466
<212> DNA
<213> Homo sapiens

<400> 23
atggatagtc gccacacctt tgcccctgct gcgatgaccc tgtcgccact tctgctgttc 60
ctgccaccgc tgctgctgct gctggacgtc ccacggcgg cggcgcaggc gtcccctctg 120
caagcgtttag acttcttttg gaatgggcca ccagttaact acaagacagg caatctatac 180
ctgcgggggc ccctgaagaa gtccaatgca ccgcttgta atgtgaccct ctactatgaa 240
gcactgtgcg gtggctgccg agccttcctg atccgggagc tcttcccaac atggctgttg 300
gtcatggaga tcctcaatgt cacgctgggtg ccctacggaa acgcacagga acaaaatgtc 360
agtggcaggt gggagttcaa gtgccagcat ggagaagagg agtgcaaatt caacaagggtg 420
gaggcctgcg tgttggatga acttgacatg gagctagcct tcctga 466

<210> 24
<211> 32
<212> PRT
<213> Homo sapiens

<400> 24
Met His Trp Glu Glu Ala Gln Ile Ser Arg Ala Val Leu Ser Leu Pro
1 5 10 15

Arg Ile Asp Leu Cys Val Ser Pro Asn Lys Leu Thr Tyr Ser Pro Lys
20 25 30

<210> 25
<211> 98
<212> PRT
<213> Homo sapiens

<400> 25
Met Glu Phe Asn Thr Thr His Tyr Arg Glu Phe Gly Pro Arg Gly Gln
1 5 10 15

Glu Phe Gly Thr Arg Gln Gln Gln Gln Lys Lys Thr Glu His Leu
20 25 30

His Ile Thr Asp Thr Gln Phe Lys Lys Gln Asn Ile Thr Ala Pro Ser
35 40 45

Arg Ile Phe Leu Gly Ser Leu Pro Ser Leu Leu Thr Pro Asp Tyr Lys
50 55 60

NEU-119.P.1, Sequence Listing

Gln Pro Pro Pro Ile Ser Pro Asp Ile Val Leu Tyr Glu Ser Ser Ser
65 70 75 80

Ser Gln Met Gly Leu Phe Cys Pro Leu Gly Thr Leu Gly Ser Ile Trp
85 90 95

Arg His

<210> 26
<211> 663
<212> PRT
<213> Homo sapiens

<400> 26

Met Ile Val Gln Met Thr Val Ile Leu Lys Leu Glu Met Pro Gln Asp
1 5 10 15

Ser Leu Ile Leu Glu Lys Ser Gln Asn Trp Ser Ser Gln Lys Met Asp
20 25 30

His Ile Leu Ile Cys Cys Val Cys Leu Gly Asp Asn Ser Glu Asp Ala
35 40 45

Asp Glu Ile Ile Gln Cys Asp Asn Cys Gly Ile Thr Val His Glu Gly
50 55 60

Cys Tyr Gly Val Asp Gly Glu Ser Asp Ser Ile Met Ser Ser Ala Ser
65 70 75 80

Glu Asn Ser Thr Glu Pro Trp Phe Cys Asp Ala Cys Lys Cys Gly Val
85 90 95

Ser Pro Ser Cys Glu Leu Cys Pro Asn Gln Asp Gly Ile Phe Lys Glu
100 105 110

Thr Asp Ala Gly Arg Trp Val His Ile Val Cys Ala Leu Tyr Val Pro
115 120 125

Gly Val Ala Phe Gly Asp Ile Asp Lys Leu Arg Pro Val Thr Leu Thr
130 135 140

Glu Met Asn Tyr Ser Lys Tyr Gly Ala Lys Glu Cys Ser Phe Cys Glu
145 150 155 160

Asp Pro Arg Phe Ala Arg Thr Gly Val Cys Ile Ser Cys Asp Ala Gly
165 170 175

NEU-119.P.1, Sequence Listing

Met Cys Arg Ala Tyr Phe His Val Thr Cys Ala Gln Lys Glu Gly Leu
180 185 190

Leu Ser Glu Ala Ala Ala Glu Glu Asp Ile Ala Asp Pro Phe Phe Ala
195 200 205

Tyr Cys Lys Gln His Ala Asp Arg Leu Asp Arg Lys Trp Lys Arg Lys
210 215 220

Asn Tyr Leu Ala Leu Gln Ser Tyr Cys Lys Met Ser Leu Gln Glu Arg
225 230 235 240

Glu Lys Gln Leu Ser Pro Glu Ala Gln Ala Arg Ile Asn Ala Arg Leu
245 250 255

Gln Gln Tyr Arg Ala Lys Ala Glu Leu Ala Arg Ser Thr Arg Pro Gln
260 265 270

Ala Trp Val Pro Arg Glu Lys Leu Pro Arg Pro Leu Thr Ser Ser Ala
275 280 285

Ser Ala Ile Arg Lys Leu Met Arg Lys Ala Glu Leu Met Gly Ile Ser
290 295 300

Thr Asp Ile Phe Pro Val Asp Asn Ser Asp Thr Ser Ser Ser Val Asp
305 310 315 320

Gly Arg Arg Lys His Lys Gln Pro Ala Leu Thr Ala Asp Phe Val Asn
325 330 335

Tyr Tyr Phe Glu Arg Asn Met Arg Met Ile Gln Ile Gln Glu Asn Met
340 345 350

Ala Glu Gln Lys Asn Ile Lys Asp Lys Leu Glu Asn Glu Gln Glu Lys
355 360 365

Leu His Val Glu Tyr Asn Lys Leu Cys Glu Ser Leu Glu Glu Leu Gln
370 375 380

Asn Leu Asn Gly Lys Leu Arg Ser Glu Gly Gln Gly Ile Trp Ala Leu
385 390 395 400

Leu Gly Arg Ile Thr Gly Gln Lys Leu Asn Ile Pro Ala Ile Leu Arg
405 410 415

Ala Pro Lys Glu Arg Lys Pro Ser Lys Lys Glu Gly Gly Thr Gln Lys
Page 17

NEU-119.P.1, Sequence Listing

420

425

430

Thr Ser Thr Leu Pro Ala Val Leu Tyr Ser Cys Gly Ile Cys Lys Lys
435 440 445

Asn His Asp Gln His Leu Leu Leu Cys Asp Thr Cys Lys Leu His
450 455 460

Tyr His Leu Gly Cys Leu Asp Pro Pro Leu Thr Arg Met Pro Arg Lys
465 470 475 480

Thr Lys Asn Ser Tyr Trp Gln Cys Ser Glu Cys Asp Gln Ala Gly Ser
485 490 495

Ser Asp Met Glu Ala Asp Met Ala Met Glu Thr Leu Pro Asp Gly Thr
500 505 510

Lys Arg Ser Arg Arg Gln Ile Lys Glu Pro Val Lys Phe Val Pro Gln
515 520 525

Asp Val Pro Pro Glu Pro Lys Lys Ile Pro Ile Arg Asn Thr Arg Thr
530 535 540

Arg Gly Arg Lys Arg Ser Phe Val Pro Glu Glu Glu Lys His Glu Glu
545 550 555 560

Arg Val Pro Arg Glu Arg Arg Gln Arg Gln Ser Val Leu Gln Lys Lys
565 570 575

Pro Lys Ala Glu Asp Leu Arg Thr Glu Cys Ala Thr Cys Lys Gly Thr
580 585 590

Gly Asp Asn Glu Asn Leu Val Arg Cys Asp Glu Cys Arg Leu Cys Tyr
595 600 605

His Phe Gly Cys Leu Asp Pro Pro Leu Lys Lys Ser Pro Lys Gln Thr
610 615 620

Gly Tyr Gly Trp Ile Cys Gln Glu Cys Asp Ser Ser Ser Ser Lys Glu
625 630 635 640

Asp Glu Asn Glu Ala Glu Arg Lys Asn Ile Ser Gln Glu Leu Asn Met
645 650 655

Glu Gln Lys Asn Pro Lys Lys
660

NEU-119.P.1, Sequence Listing

<210> 27
 <211> 372
 <212> PRT
 <213> Homo sapiens

<400> 27

Met Ser Lys Ala Phe Gly Leu Leu Arg Gln Ile Cys Gln Ser Ile Leu
 1 5 10 15

Ala Glu Ser Ser Gln Ser Pro Ala Asp Leu Glu Glu Lys Lys Glu Glu
 20 25 30

Asp Ser Asn Met Lys Arg Glu Gln Pro Arg Glu Arg Pro Arg Ala Trp
 35 40 45

Asp Tyr Pro His Gly Leu Val Gly Leu His Asn Ile Gly Gln Thr Cys
 50 55 60

Cys Leu Asn Ser Leu Ile Gln Val Phe Val Met Asn Val Asp Phe Thr
 65 70 75 80

Arg Ile Leu Lys Arg Ile Thr Val Pro Arg Gly Ala Asp Glu Gln Arg
 85 90 95

Arg Ser Val Pro Phe Gln Met Leu Leu Leu Glu Lys Met Gln Asp
 100 105 110

Ser Arg Gln Lys Ala Val Arg Pro Leu Glu Leu Ala Tyr Cys Leu Gln
 115 120 125

Lys Cys Asn Val Pro Leu Phe Val Gln His Asp Ala Ala Gln Leu Tyr
 130 135 140

Leu Lys Leu Trp Asn Leu Ile Lys Asp Gln Ile Thr Asp Val His Leu
 145 150 155 160

Val Glu Arg Leu Gln Ala Leu Tyr Met Ile Arg Val Lys Asp Ser Leu
 165 170 175

Ile Cys Val Asp Cys Ala Met Glu Ser Ser Arg Asn Ser Ser Met Leu
 180 185 190

Thr Leu Pro Leu Ser Leu Phe Asp Val Asp Ser Lys Pro Leu Lys Thr
 195 200 205

Leu Glu Asp Ala Leu His Cys Phe Phe Gln Pro Arg Glu Leu Ser Ser
 210 215 220

NEU-119.P.1, Sequence Listing

Lys Ser Lys Cys Phe Cys Glu Asn Cys Gly Lys Lys Thr Arg Gly Lys
225 230 235 240

Gln Val Leu Lys Leu Thr His Leu Pro Gln Thr Leu Thr Ile His Leu
245 250 255

Met Arg Phe Ser Ile Arg Asn Ser Gln Thr Arg Lys Ile Cys His Ser
260 265 270

Leu Tyr Phe Pro Gln Ser Leu Asp Phe Ser Gln Ile Leu Pro Met Lys
275 280 285

Arg Glu Ser Cys Asp Ala Glu Glu Gln Ser Gly Gly Gln Tyr Glu Leu
290 295 300

Phe Ala Val Ile Ala His Val Gly Met Ala Asp Ser Gly His Tyr Cys
305 310 315 320

Val Tyr Ile Arg Asn Ala Val Asp Gly Lys Trp Phe Cys Phe Asn Asp
325 330 335

Ser Asn Ile Cys Leu Val Ser Trp Glu Asp Ile Gln Cys Thr Tyr Gly
340 345 350

Asn Pro Asn Tyr His Trp Gln Glu Thr Ala Tyr Leu Leu Val Tyr Met
355 360 365

Lys Met Glu Cys
370

<210> 28
<211> 71
<212> PRT
<213> Homo sapiens

<400> 28

Met Ala Ala Ala Leu Leu Pro Ser Gly Gln Asn Trp His Asn Thr Gly
1 5 10 15

Phe Ile Leu Glu Ser Asn Leu Thr Asn Val Met Lys Val Val Arg Leu
20 25 30

Phe Ile Lys Cys Pro Cys Leu Trp Gly His Glu Lys Ile His Thr Glu
35 40 45

Ser Ile Lys Asn Val Leu Asn Met Glu Arg Pro Leu Ser Asn Ser Asp
50 55 60

NEU-119.P.1, Sequence Listing

Val Met Lys Val Val Val Phe
65 70

<210> 29
<211> 302
<212> PRT
<213> Homo sapiens

<400> 29

Met Cys Thr Leu Cys Thr Val Met Lys Ser Gly Asn Gly Arg Gly Glu
1 5 10 15

Lys Asp Gly His Pro Leu Thr Ser Ser Leu Lys Ile Pro Thr Ala Ser
20 25 30

Gln Gly Ser Ala Pro Cys Arg Ser Lys Val Gly Val Gly Leu Gly Glu
35 40 45

Met Leu Pro Ile Phe Gln Gly Leu Leu Cys Phe Trp Ser Pro Gly Asn
50 55 60

Arg Cys Cys Leu Glu Leu Trp Arg Glu Gly Phe His Pro Ala Pro Thr
65 70 75 80

Ile Pro Leu Leu Phe His Thr Leu Ala Cys Gly Trp Ser Leu Thr Gly
85 90 95

Leu Val Arg Val Ala Cys Asp Leu Arg Leu Leu Val Pro Gly His Phe
100 105 110

Trp Asn Phe Gly Lys Met Cys Cys Phe Ala Ser Gly Arg Leu Tyr Leu
115 120 125

Val Ala Gly Thr Leu Cys Pro Gln His Thr Phe Phe Cys Asp Ser Arg
130 135 140

Gln Lys Gly Gln Met Gln Lys Gln Asn Gly Gly Lys Ala Val Asp Glu
145 150 155 160

Arg Gln Leu Phe His Gly Thr Ser Ala Ile Phe Val Asp Ala Ile Cys
165 170 175

Gln Gln Asn Phe Asp Trp Arg Val Cys Gly Val His Gly Thr Ser Tyr
180 185 190

Gly Lys Gly Ser Tyr Phe Ala Arg Asp Ala Ala Tyr Ser His His Tyr
195 200 205

NEU-119.P.1, Sequence Listing

Ser Lys Ser Asp Thr Gln Thr His Thr Met Phe Leu Ala Arg Val Leu
210 215 220

Val Gly Glu Phe Val Arg Gly Asn Ala Ser Phe Val Arg Pro Pro Ala
225 230 235 240

Lys Glu Gly Trp Ser Asn Ala Phe Tyr Asp Ser Cys Val Asn Ser Val
245 250 255

Ser Asp Pro Ser Ile Phe Val Ile Phe Glu Lys His Gln Val Tyr Pro
260 265 270

Glu Tyr Val Ile Gln Tyr Thr Thr Ser Ser Lys Pro Ser Val Thr Pro
275 280 285

Ser Ile Leu Leu Ala Leu Gly Ser Leu Phe Ser Ser Arg Gln
290 295 300

<210> 30
<211> 31
<212> PRT
<213> Homo sapiens

<400> 30

Met Pro Val Tyr Gly Ile Asn Pro His Leu Thr Phe Gln Pro Ala Ser
1 5 10 15

Leu Pro Tyr Gly Phe Arg Thr Cys Gln Pro His Asn Ser Leu Lys
20 25 30

<210> 31
<211> 95
<212> PRT
<213> Homo sapiens

<400> 31

Met Leu Ile Glu Asp Val Asp Ala Leu Lys Ser Trp Leu Ala Lys Leu
1 5 10 15

Leu Glu Pro Ile Cys Asp Ala Asp Pro Ser Ala Leu Ala Asn Tyr Val
20 25 30

Val Ala Leu Val Lys Lys Asp Lys Pro Glu Lys Glu Leu Lys Ala Phe
35 40 45

Cys Ala Asp Gln Leu Asp Val Phe Leu Gln Lys Glu Thr Ser Gly Phe
50 55 60

Val Asp Lys Leu Phe Glu Ser Leu Tyr Thr Lys Asn Tyr Leu Pro Leu
Page 22

NEU-119.P.1, Sequence Listing

65 70 75 80

Leu Glu Pro Val Lys Pro Glu Pro Lys Pro Leu Ala Gln Glu Lys
85 90 95

<210> 32
<211> 261
<212> PRT
<213> Homo sapiens

<400> 32

Met Asp Ser Arg His Thr Phe Ala Pro Ala Ala Met Thr Leu Ser Pro
1 5 10 15

Leu Leu Leu Phe Leu Pro Pro Leu Leu Leu Leu Asp Val Pro Thr
20 25 30

Ala Ala Val Gln Ala Ser Pro Leu Gln Ala Leu Asp Phe Phe Gly Asn
35 40 45

Gly Pro Pro Val Asn Tyr Lys Thr Gly Asn Leu Tyr Leu Arg Gly Pro
50 55 60

Leu Lys Lys Ser Asn Ala Pro Leu Val Asn Val Thr Leu Tyr Tyr Glu
65 70 75 80

Ala Leu Cys Gly Gly Cys Arg Ala Phe Leu Ile Arg Glu Leu Phe Pro
85 90 95

Thr Trp Leu Leu Val Met Glu Ile Leu Asn Val Thr Leu Val Pro Tyr
100 105 110

Gly Asn Ala Gln Glu Gln Asn Val Ser Gly Arg Trp Glu Phe Lys Cys
115 120 125

Gln His Gly Glu Glu Glu Cys Lys Phe Asn Lys Val Glu Ala Cys Val
130 135 140

Leu Asp Glu Leu Asp Met Glu Leu Ala Phe Leu Thr Ile Val Cys Met
145 150 155 160

Glu Glu Phe Glu Asp Met Glu Arg Ser Leu Pro Leu Cys Leu Gln Leu
165 170 175

Tyr Ala Pro Gly Leu Ser Pro Asp Thr Ile Met Glu Cys Ala Met Gly
180 185 190

Asp Pro Gly Met Gln Leu Met His Ala Asn Ala Gln Arg Thr Asp Ala
Page 23

NEU-119.P.1, Sequence Listing

195

200

205

Leu Gln Pro Pro His Glu Tyr Val Pro Trp Val Thr Val Asn Gly Lys
210 215 220

Pro Leu Glu Asp Gln Thr Gln Leu Leu Thr Leu Val Cys Gln Leu Tyr
225 230 235 240

Gln Gly Lys Lys Pro Asp Val Cys Pro Ser Ser Thr Ser Ser Leu Arg
245 250 255

Ser Val Cys Phe Lys
260

<210> 33
<211> 21
<212> PRT
<213> Homo sapiens

<400> 33

Met Pro Gly Tyr Arg His Cys Thr Pro Ala Trp Val Thr Glu Arg Asp
1 5 10 15

Ser Val Ser Glu Lys
20